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Abstract
Background: The PAM50-based (Prosigna) risk of recurrence (ROR) score and intrinsic subtypes are prognostic for
women with high-risk breast cancer. We investigate the predictive ability of Prosigna regarding the effectiveness of
cyclophosphamide-based adjuvant chemotherapy in premenopausal patients with high-risk breast cancer.
Methods: Prosigna assays were performed on the NanoString platform in tumors from participants in Danish Breast
Cancer Group (DBCG) 77B, a four-arm trial that randomized premenopausal women with high-risk early breast
cancer to no systemic treatment, levamisole, oral cyclophosphamide (C) or cyclophosphamide, methotrexate and
fluorouracil (CMF).
Results: In total, this retrospective analysis included 460 women (40% of the 1146 randomized patients). The continuous
Prosigna ROR score was prognostic in the no systemic treatment group (unadjusted P < 0.001 for disease-free survival
(DFS), P = 0.001 for overall survival (OS)). No statistically significant interaction of continuous ROR score and treatment on
DFS and OS was found. A highly significant association was observed between intrinsic subtypes and C/CMF treatment
for DFS (Pinteraction = 0.003 unadjusted, P = 0.001 adjusted) and OS (Pinteraction = 0.04). In the adjusted analysis treatment
with C/CMF was associated with a reduced risk of DFS events in patients with basal-like (hazard ratio (HR)
0.14; 95% CI 0.06; 0.32) and luminal B (HR 0.48; 95% CI 0.27; 0.84) subtypes but not in patients with Human
epidermal growth factor receptor-enriched (HR 1.05; 95% CI 0.56; 1.95) or luminal A (HR 0.61; 95% CI 0.32; 1.16) subtypes.
Conclusion: The Prosigna ROR score and intrinsic subtypes were prognostic in high-risk premenopausal
patients with breast cancer, and intrinsic subtypes identify high-risk patients with or without major benefit
from adjuvant C/CMF treatment.
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Background
The early results of the first adjuvant Milan trial were
published in 1976 [1], and showed a clear benefit from
4-weekly oral cyclophosphamide on days 1 to 14 com-
bined with intravenous methotrexate and fluorouracil on
days 1 and 8 (CMF). The Milan trial included patients
with high-risk (node-positive) breast cancer who were
randomized after mastectomy; none of whom received
radiotherapy or endocrine treatment. Several cooperative
groups, including the Danish Breast Cancer Group
(DBCG), initiated trials to explore the results from the
pivotal Milan trial. DBCG 77B included premenopausal
patients with high-risk breast cancer who after mastec-
tomy and radiotherapy and without endocrine treatment
were randomized to observation, levamisole, single-agent
cyclophosphamide, or CMF. Results showed a similar
benefit from oral cyclophosphamide and CMF, and the
survival benefit was maintained after 25 years of follow up
[2]. Due to the results of these and other early clinical
trials, adjuvant chemotherapy has been considered a
standard in premenopausal patients with node-positive
breast cancer since the National Institutes of Health Con-
sensus Conference in 1980 [3]. Subsequent meta-analyses
by the Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) have demonstrated that the relative benefit of
CMF was largely independent of patient characteristics,
nodal status and other tumor features available for
analysis, and also independent of the use of concomitant
tamoxifen. Furthermore, in the EBCTCG analysis an add-
itional incremental benefit was shown from adding an
anthracycline to CMF, from substituting methotrexate
with doxorubicin or epirubicin, and from giving taxanes
concurrently or in sequence with anthracyclines [4, 5].
Since intrinsic molecular subtypes were first described
more than 15 years ago, their prognostic ability has re-
peatedly been demonstrated in early breast cancer [6].
However, few attempts have been made to explore the
ability of these subtypes to predict benefit of chemother-
apy. The prediction analysis of microarray 50 (PAM50)
gene set has become a standard for identifying intrinsic
subtypes from RNA expression measurements and its
predictive abilities have been evaluated in the Canadian
MA.5 trial comparing adjuvant cyclophosphamide, epir-
ubicin, and fluoroucil (CEF) to CMF in patients with
early breast cancer. The human epidermal growth factor
receptor 2 (Her2)-enriched subtype was associated with
a benefit from the anthracycline-containing chemother-
apy arm while no significant differences between arms
were shown for patients with basal-like, luminal A or lu-
minal B breast cancers [7]. Additionally, a high 21-gene
recurrence score (OncotypeDx) has been associated with
benefit from addition of cyclophosphamide, adriamycin,
and fluorouracil (CAF) to tamoxifen [8] in high-risk
node-positive disease, suggesting that not all patients
with high-risk early breast cancer derive a similar benefit
from adjuvant chemotherapy.
The PAM50 gene signature has been developed into a
clinical test, the Prosigna gene signature assay, validated to
estimate the prognosis for postmenopausal patients with es-
trogen receptor (ER)+ early-stage breast cancer [9, 10]. In
the DBCG 77B trial we randomized premenopausal patients
with high-risk breast cancer to cyclophosphamide-based
chemotherapy against no systemic treatment, and the two
primary co-objectives of this study were to evaluate the
predictive ability of the PAM50-based Prosigna risk of
recurrence (ROR) score and intrinsic subtypes.
Methods
Details on DBCG 77B have been published previously
[2]. In brief, this was an open-label randomized phase III
trial comparing, in the adjuvant setting, radiotherapy
alone (control), radiotherapy plus 2.5 mg/kg/body weight
of levamisole on 2 days consecutively each week for
48 weeks, radiotherapy plus 12 cycles of single-agent
cyclophosphamide (C) 130 mg/m2 orally on days 1–14
every 4 weeks, or radiotherapy plus 12 cycles of CMF
(cyclophosphamide 80 mg/m2 orally on days 1–14,
methotrexate 30 mg/m2 intravenously on days 1 and 8,
and 5-fluorouracil 500 mg/m2 intravenously on days 1
and 8) every 4 weeks. Patients were eligible for DBCG
77B if they were without distant metastasis, were pre-
menopausal, and had either positive lymph nodes, tu-
mors > 5 cm, and/or invasion of the deep fascia. The
DBCG prepared the original 77B trial and its biological
sub-studies have previously been described in detail [2, 11].
The Biomedical Research Ethics of the Danish Capital
Region approved the protocol (H-15012740).
Central assessment of Prosigna
Formalin-fixed, paraffin-embedded tumor blocks (FFPE)
from primary excisional surgery specimens were col-
lected at the Department of Pathology, Zealand Univer-
sity Hospital. RNA extraction and Prosigna testing were
performed according to standard operating procedures
[9] by investigators blinded to clinical outcome. Prosigna
results were transferred to the data manager at Nano-
string, who while remaining blinded to clinical data, pre-
pared the Prosigna ROR and intrinsic subtype analysis
data set. This was forwarded to the DBCG statistical of-
fice for merging with clinical data and to execute the
prespecified statistical analysis plan. ROR cut offs for
analysis of the combined study population (including ER
+/− and Her2+/−) were prespecified in terms of the ob-
served ROR score distribution tertiles within the study
population (8–51 (low), 52–71 (intermediate), and 72–
100 (high)) and were independent of nodal status.
The age of the FFPE tissue blocks resulted in de-
creased RNA quality compared with previous studies
Jensen et al. Breast Cancer Research  (2018) 20:79 Page 2 of 10
performed by the DBCG. In order to increase power for
the exploratory analysis in the ER+/Her2- population,
the Prosigna test quality control criteria for RNA quality
was relaxed for this subset.
Statistical methods
A written prespecified statistical analysis plan was final-
ized prior to data analysis. The statistical analysis was
executed by the DBCG statistical office, which was not
involved in biomarker data collection. The primary end-
point for this study was disease-free survival (DFS), de-
fined as time from randomization to any first event of
invasive ipsilateral or contralateral breast cancer recur-
rence, local or regional invasive recurrence, distant re-
currence, second (non-breast) invasive cancer, or death
from any cause. The secondary endpoint was overall sur-
vival (OS), defined as time from date of randomization
until death from any cause. Survival rates were estimated
by the Kaplan-Meier method. Patients treated according
to protocol were included. Cox proportional hazards re-
gression models were applied to assess the unadjusted
and adjusted hazard ratios (HR). The chemotherapy
arms (C + CMF) were analyzed versus no chemotherapy
arms (control + levamisole). The multivariate models in-
cluded age at entry (≤ 40, 41–45, 46–50, and 50 years),
tumor size (≤ 2, > 2 to ≤ 5, and > 5 cm), lymph node
(LN) status (0–3 positive LN, 4–9, 10+ and < 10 vs 10+
retrieved), histologic type (ductal vs non-ductal), grade
(ductal I, II, and III) and treatment regimen. Propor-
tional hazards assumptions were assessed using Schoen-
feld residuals and by including a time-dependent
component for each covariate. The hazard rates for
histologic type and grade were not proportional; there-
fore, stratification was used. To comply with propor-
tional hazards assumptions about subtypes and ROR
score, separate estimates were included according to time
since randomization. The Wald test was used to assess
heterogeneity. Associations between included and ex-
cluded patients and clinico-pathological characteristics
(excluding unknowns) were analyzed using the chi-square
test. P values are two-tailed, unadjusted for number of
comparisons. Central review, monitoring, and statistical
analyses were done by the DBCG Statistical Office using
the SAS 9.4 software program package (SAS Institute,
Cary, NC, USA).
Results
The DBCG 77B trial enrolled 1146 patients, among
whom 1072 received treatment as allocated by
randomization (Additional file 1: Figure S1). Tumor
blocks were available from 649 patients, and 623 blocks
contained sufficient invasive breast cancer tissue for
RNA extraction. The Prosigna assay was successful in
487 patients, of which 460 were treated according to
protocol. The assessable 460 patients did differ signifi-
cantly from the 612 non-assessable patients (P < 0.05)
with regard to histologic type (P = 0.03) and malignancy
grade (P = 0.02). Among the 460 patients, 231 (81%) ex-
perienced a first event within 10 years. Number of posi-
tive lymph nodes, tumor size, age, and treatment
regimen were not significantly different in assessable vs
non-assessable patients. The treatment effect was similar
with an HR favoring chemotherapy for DFS (adjusted
HR; 0.55; 95% CI, 0.38 to 0.79; P = 0.001) to the effect
observed in the original study (HR = 0.60; 95% CI, 0.48
to 0.75). Table 1 shows the baseline characteristics ac-
cording to Prosigna subtype for the 460 patients: 324 pa-
tients were included in the exploratory analysis of DFS
in the ER+/Her2− patient population.
Of the 460 patients included in the primary analyses
61 (13%) were classified as having basal-like, 120 (26%)
as Her2-enriched, 161 (35%) as luminal A and 116 (25%)
as luminal B breast cancer, reflecting the population in-
cluding patients with ER+/− and Her2+/− breast cancer.
Prognosis by Prosigna ROR score
The continuous ROR score was highly prognostic (un-
adjusted HR, 1.23; 95% CI, 1.09 to 1.39, P < 0.001 for a
10-point difference) for DFS within the group not
treated systemically. For the C/CMF-treated group, the
ROR continuous score had a different effect according
to follow-up time (0–5 years vs 5+ years) (Fig. 1a and b).
The ROR prognosis was statistically significant for the
first 5 years for both the C/CMF arm and the no chemo-
therapy arm, and with no differential effect, whereas
after 5 years no prognostic effect was apparent. There
was no statistically significant differential effect accord-
ing to follow-up time in the no chemotherapy arm alone.
Including all patients, irrespective of hormone receptor
status, the 10-year DFS rates in the untreated group
were 62% (95% CI, 43 to 76), 27% (95% CI, 14 to 43)
and 27% (95% CI, 15 to 41) for low, intermediate, and
high ROR scores, respectively (Fig. 2a). Comparing inter-
mediate ROR with low-risk ROR for the untreated
group, unadjusted HR = 2.66; 95% CI, 1.35 to 5.24, and
similarly for the high vs low-risk ROR group HR = 2.73;
95% CI, 1.43 to 5.22. Likewise, the ROR score was prog-
nostic for OS in the untreated group (Fig. 2b) and the
10-year OS rates were 63% (95% CI, 45 to 76), 38% (95%
CI, 22 to 54), and 30% (95% CI, 17 to 43) for low, inter-
mediate, and high ROR scores, respectively.
Effect of chemotherapy according to the Prosigna ROR
score
For the first co-primary objective, we examined the asso-
ciation between the continuous Prosigna ROR score and
benefit of chemotherapy in the population including pa-
tients with ER+/− and Her2+/− breast cancer. There
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Table 1 Patient and tumor characteristics by Prosigna (PAM50) subtype
Total study set Molecular subtype
Luminal A Luminal B Basal-like Her2-E
Characteristics N % N % N % N % N %
Number of patients 460 – 161 35 118 27 61 13 120 26
Age
< 40 years 96 21 23 14 26 22 19 31 28 23
40–49 years 233 51 94 58 63 53 25 41 51 43
50–59 years 131 28 44 27 29 25 17 28 41 34
Lymph nodes excised
None 19 4 8 5 7 6 1 2 3 3
1–3 110 24 42 26 27 23 14 23 27 23
4–9 268 58 97 60 67 57 39 64 65 54
> 9 6 14 14 9 17 14 7 11 25 21
Lymph node status
Negative 43 9 16 10 4 3 10 16 13 11
1–3 positive 271 59 106 66 72 61 33 54 60 50
4+ positive 127 28 31 19 35 30 17 28 44 37
Unknown 19 4 8 5 7 6 1 2 3 3
Tumor size
0–20 mm 132 29 60 37 36 31 14 23 22 18
21–50 mm 239 52 77 48 61 52 30 49 71 59
> 50 mm 85 18 24 15 21 18 13 21 27 23
Unknown 4 1 0 0 0 0 4 7 0 0
Deep fascia invasion
Absent 346 75 127 79 93 79 45 74 81 68
Present 109 24 32 20 25 21 15 25 37 31
Unknown 5 1 2 1 0 0 1 2 2 2
Histologic type
Ductal carcinoma 393 85 132 82 99 84 52 85 110 92
Lobular carcinoma 33 7 16 10 13 11 1 2 3 3
Other 28 6 11 7 5 4 6 10 6 5
Unknown 6 1 2 1 1 1 2 3 1 1
Malignancy gradea
Grade I 65 17 46 35 15 15 1 2 3 3
Grade II 242 62 81 61 73 74 22 42 66 60
Grade III 86 22 5 4 11 11 29 56 41 37
HR status
Positive 329 72 146 91 112 95 6 10 65 54
Negative 114 25 6 4 5 4 52 85 51 43
Unknown 17 4 9 6 1 1 3 5 4 3
Systemic treatment
Control or levamisole 113 25 37 23 34 29 10 16 32 27
C or CMF 347 75 124 77 84 71 51 84 88 73
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Fig. 1 a Disease-free survival by continuous risk of recurrence (ROR) score 0–5 years and 5–10 years after randomization, respectively, for patients
in the systemically untreated regimen (CT –) and patients in the C/CMF arm (CT +). b Overall survival by continuous ROR score for 0–5 years and
5+ years after randomization, respectively. Hazard ratios and corresponding 95% CI for a 10-point difference in continuous ROR score are shown
Table 1 Patient and tumor characteristics by Prosigna (PAM50) subtype (Continued)
Total study set Molecular subtype
Luminal A Luminal B Basal-like Her2-E
Characteristics N % N % N % N % N %
ROR score groups
Low (0–51) 155 34 135 84 2 2 14 23 4 3
Intermediate (52–71) 148 32 26 16 50 42 40 66 32 27
High (72–100) 157 34 0 0 66 56 7 11 84 70
PAM50 prediction analysis of microarray 50, C cyclophosphamide, CMF cyclophosphamide, methotrexate and fluorouracil, HR hormone receptor, Her2-E human
epidermal growth factor receptor 2-enriched, ROR risk of recurrence
aDuctal carcinomas only
Jensen et al. Breast Cancer Research  (2018) 20:79 Page 5 of 10
was no significant effect of the ROR score on treatment;
for the continuous ROR score Pinteraction = 0.66 for DFS
and Pinteraction = 0.32 for OS, in unadjusted models. The
benefit for DFS was significant for both intervals of
intermediate (52–71) and high (72–100) Prosigna ROR
scores, whereas there was a smaller, non-significant
benefit for low (0–51) ROR scores, although interactions
between ROR score groups and benefit of chemotherapy
were not statistically significant (Table 2 for unadjusted
results) (Pinteraction = 0.47), also true for OS (Pinteraction =
0.24). The HR for impact of the continuous ROR as the
impact of the predefined intervals remained largely un-
changed following adjustment for patients and tumor
characteristics (Fig. 3a and b).
Prosigna has been validated and is indicated for use in
ER+, Her2− disease only, therefore, an underpowered
but planned exploratory analysis of DFS in the ER+,
Her2- subset was also executed using the risk groups de-
fined by the commercial cut point of low-risk ROR ≤ 40.
A benefit from chemotherapy was observed in the high--
risk group (HR = 0.48, 95% CI, 0.33 to 0.69) while no
benefit was demonstrated in the low-risk group (HR
= 1.13, 95% CI, 0.42 to 3.07); however, no there was
no statistically significant interaction between ROR
risk groups and treatment effect (unadjusted Pinteraction
= 0.11) (Additional file 2: Figure S2) and (adjusted Pinterac-
tion = 0.10).
Effect of chemotherapy for Prosigna intrinsic subtype
groups
For the second co-primary objective, we examined the as-
sociation between Prosigna intrinsic subtypes and benefit
of chemotherapy. A significant interaction was observed
between Prosigna subtype and treatment (Table 2) for
DFS (Pinteraction = 0.003) and OS (Pinteraction = 0.04), with
the subtypes included separately. Statistically significant
interactions between the Prosigna subtypes and treatment
remained after multivariate adjustment both for DFS
a b
Fig. 2 a Kaplan-Meier estimates of disease-free survival in the 113 patients systemically untreated (– CT), according to low, intermediate, and high
Prosigna risk of recurrence (ROR) scores. b Kaplan-Meier estimates of overall survival
Table 2 Unadjusted HR estimates of the treatment effect for DFS and OS according to Prosigna ROR scores and subtype
DFS OS
HR (95% CI) Pinteraction HR (95% CI) Pinteraction
ROR score 0.47 0.24
Low tertile 0.79 (0.42–1.47) 1.09 (0.70–1.71)
Intermediate tertile 0.49 (0.30–0.79) 0.75 (0.50–1.13)
High tertile 0.64 (0.42–0.98) 0.66 (0.46–0.96)
Subtype 0.003 0.04
Luminal A 0.64 (0.36–1.14) 0.96 (0.62–1.48)
Luminal B 0.47 (0.28–0.77) 0.51 (0.33–0.77)
Basal-like 0.19 (0.09–0.40) 0.52 (0.24–1.12)
Her2-enriched 1.04 (0.62–1.75) 1.10 (0.71–1.71)
DFS disease-free survival, OS overall survival, HR hazard ratio, ROR risk of recurrence, 95% CI 95% confidence interval, Pinteraction P derived from a Wald test for
heterogeneity, Her2 human epidermal growth factor receptor 2
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(Fig. 3a) and OS (Fig. 3b). Patients with a basal-like
subtype of breast cancer had a pronounced benefit
from cyclophosphamide-based adjuvant chemotherapy
(unadjusted HR, 0.19; 95% CI, 0.09 to 0.40), and a
marked benefit was also obtained by those with the
luminal B subtype (unadjusted HR, 0.47; 95% CI, 0.28
to 0.77) (Fig. 4). While there was significant benefit
from chemotherapy on DFS in both the subgroups
with basal-like and luminal B subtype breast cancer,
there was no effect in women with Her2-enriched tu-
mors, and a less pronounced effect in those with lu-
minal A tumors (Padjusted = 0.001). The benefit was
not significantly different in patients with the luminal
A subtype from those with the luminal B subtype
(Padjusted = 0.52) or from those with non-Luminal A
subtype tumors combined (Padjusted = 0.87). For OS
the corresponding figures are Padjusted = 0.09 and
Padjusted = 0.32.
Discussion
Premenopausal patients with high-risk breast cancer are
generally recommended chemotherapy, but our study
suggests that patients with tumors from different intrin-
sic molecular subtypes do not benefit equally from
cyclophosphamide or CMF-based adjuvant chemother-
apy. When considering a heterogeneous population of
patients with ER+/− and Her2+/− disease, the continu-
ous Prosigna ROR score was shown to be significantly
associated with prognosis. The Prosigna ROR score was
not significantly predictive of treatment effect in a popu-
lation combining ER+/− and Her2+/− patients. However,
the biology of these disease subtypes is dramatically dif-
ferent and it is not unexpected that a score developed to
predict disease recurrence in ER+ Her2− patients does
not predict benefit from chemotherapy across all ER+/−
and Her2+/− patients. By focusing on the more
homogenous population of ER+, Her2− patients we did
observe a benefit from chemotherapy in the high-risk
population and no benefit in the low-risk population
though similarly, we found no statistically significant
heterogeneity of treatment effect according to ROR
score. This subset analysis was hindered by the limited
number of patients included, especially for the group
not treated with chemotherapy.
More crucially, a significantly different and clinically
relevant benefit was obtained based on the major intrin-
sic subtypes as assigned by Prosigna. The use of
cyclophosphamide-based chemotherapy in patients with
basal-like breast cancer was associated with an 86% rela-
tive reduction in DFS events and a 56% relative reduc-
tion in mortality. Patients with luminal B disease also
had a statistically significant benefit from chemotherapy,
albeit to a lesser degree (39% reduction in DFS events and
in mortality). In contrast, patients with tumors of the
Her2-enriched subtype and luminal A subtype obtained
no statistically measurable benefit. The gain obtained by
patients with a luminal A subtype however, did not signifi-
cantly differ from those with a luminal B nor from those
with a non-luminal A subtype taken together.
This heterogeneity in benefit from chemotherapy ac-
cording to the intrinsic subtypes explains the lack of as-
sociation between the ROR score and benefit from
chemotherapy in the overall population. Though the tu-
mors with the lowest ROR are the luminal A subtype,
with little sensitivity to chemotherapy, a large proportion
of patients with basal-like breast cancer were assigned
intermediate ROR scores and saw a large benefit from
chemotherapy and most of the chemotherapy-insensitive
Fig. 3 Forest plots illustrate proportional hazard models for disease-free
survival (a) and overall survival (b) overall and according to intrinsic
cancer subtype and risk of recurrence (ROR) score, respectively. Hazard
ratios refer to adjusted estimates obtained in the multivariate
analysis. P values are for test of heterogeneity of treatment
effect. Boxes represent the weight of data for each subgroup
relative to the total data. Pt.s, patients; Lum, luminal; HER2E, human
epidermal growth factor receptor 2-enriched
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Her2-enriched tumors were assigned high ROR scores.
Consequently, within the overall population there is not
a monotonic relationship between the ROR score and
benefit from chemotherapy. However, when focusing on
the ER+/Her2− population, we found a more direct rela-
tionship between risk and benefit from chemotherapy,
although the analysis in this subset was not powered to
show an interaction.
Our results are complementary to the results from the
NCIC-CTG MA.5 trial, where all patients were treated
with adjuvant chemotherapy but were randomized to
CMF or CEF. Cheang and colleagues showed no added
benefit in basal-like breast cancer but identified a
substantial benefit in Her2-enriched high-risk breast
cancer from the anthracycline-containing CEF chemo-
therapy as compared to CMF [7]. The MA.5 and
DBCG 89D trials and a pooled analysis with three
additional phase III trials showed a greater benefit of
anthracyclines in patients with TOP2A alterations and
a trend towards greater benefit in patients with
Her2-amplified tumors [12–15]. More recently, the
DBCG READ trial gave no evidence to support a
benefit from anthracyclines in patients with early
TOP2A-normal breast cancer while the Anthracyclines
in early breast cancer (ABC) trials suggested that pa-
tients with Her2-normal breast cancer derive some
benefit from anthracyclines [16, 17]. The association
between the Her2-enriched subtype and alteration of
TOP2A has not yet been clarified but may improve
the clinical utility of both markers. Finally, retrospect-
ive analyses of clinical studies in the metastatic set-
ting have shown that the intrinsic subtype may
predict benefit from other specific cytotoxic agents
such as gemcitabine [18] and docetaxel [19]. Together
a b
c d
Fig. 4 Kaplan-Meier estimates of disease-free survival in patients with luminal (Lum) A (a), luminal B (b), basal-like (c), and human epidermal
growth factor receptor 2-enriched (HER2-E) (d) breast cancer in the systemically untreated arm (–CT) and in the cyclophosphamide/cyclophosphamide,
methotrexate and fluorouracil arm (+CT)
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these studies emphasize that the potential benefit to
patients with breast cancer from establishing an asso-
ciation between intrinsic subtype and type of chemo-
therapy could be significant.
In this subset we showed a distribution of subtypes
that differs from that previously demonstrated by immu-
nohistochemical analysis (IHC) using tissue microarrays
constructed from 633 patients participating in the
DBCG 77B trial [11]. The treatment effect appear less
segregated between the luminal A and B subtypes using
Prosigna compared to IHC, presumably due to the
smaller percentage of luminal A tumors identified by the
IHC definition employed in the previous study. In con-
trast, the effect obtained by an IHC definition of
core-basal cancer was less pronounced compared to
basal breast cancers as defined by Prosigna [11]. While
separate studies have shown that nucleic acid-based
methods surpass the analytical reproducibility of IHC,
our study confirms that genomic-based tests provide
also additional information on clinical benefit compared
to IHC surrogates [20, 21].
Due to the very old age of the DBCG77B study, we
were only able to collect tumor blocks to be used for
messenger (m)RNA testing from 623 of the original
1146 patients, and samples from the no chemotherapy
arms (which were closed early and recruited smaller
numbers of patients) were particularly sparse (Additional
file 1: Figure S1), reducing study power compared to the
original [2] and even to subsequent IHC studies [11] for
which more cases were available. As a consequence, the
ability to conduct subgroup analysis has been limited
e.g. the possible influence of chemotherapy-induced
amenorrhea, which may have been particularly import-
ant in patients with luminal cancers.
Beyond power concerns, this study has other potential
limitations. First, the retrospective evaluation of only a
subset of patients in the biomarker analysis introduces a
risk of bias and a residual risk may persist despite ad-
justments in the multivariate analyses. Second, the 77B
study samples analyzed here had been stored for almost
40 years resulting in significant degradation in the
mRNA in the samples. This degradation was evident in
the higher rate of samples that were unevaluable by the
assay (22%) compared to 1% in a previous study using
samples banked for a median of 10 years [22]. DBCG77B
only employed cyclophosphamide or classic CMF and
benefit of a more pronounced effect could potentially
have been obtained by more contemporary adjuvant
chemotherapy. The contribution from cyclophospha-
mide might, however, have been inseparable from the
contributions of anthracyclines, taxanes, endocrine ther-
apy, and Her2-targeted therapy, if these treatments were
combined. A possible association between molecular
tumor subtype and the individual drugs may in later
studies be obtained by identifying trials with successive
addition of anthracyclines and taxanes.
Strengths of this study include use of patients with
high-risk breast cancer derived from a phase III random-
ized trial without any biomarker selection. The inclusion
of a control group who were not systemically treated
was crucial for our ability to isolate associations between
intrinsic subtypes by Prosigna and treatment effect from
cyclophosphamide based-chemotherapy. In addition, our
study adhered carefully to the ReMARK guidelines [23],
and used the validated and Food and Drug Association
(FDA)-cleared Prosigna assay following standard operat-
ing procedures as specified by the manufacturer [24].
Conclusions
In summary, this study demonstrates that the Prosigna
assay is both prognostic and predictive of benefit from
cyclophosphamide-based adjuvant chemotherapy in pre-
menopausal patients with high-risk breast cancer. These
results provide further evidence that the high-risk intrinsic
subtypes of breast cancer have highly differential responses
to cyclophosphamide-based chemotherapy regimens, with
clear benefit in the basal-like and luminal B subtypes.
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